The anti-aging drug Senolytics alleviates vascular endothelial cell senescence by antagonizing the JPX-BRD4-p65 complex
Cellular Signalling · 2026-03 · 139 · 112342
DOI: 10.1016/j.cellsig.2025.112342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2026-03. Verfasst von Kaili Mao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang 324000, China. Hauptthemen laut MEDLINE: Cellular Senescence, Senotherapeutics, Cell Cycle Proteins, Transcription Factors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Wu Jieping Medical Foundation, Guangdong Medical Research Foundation.
Abstract (Originalsprache)
Senescence of vascular endothelial cells (ECs) and smooth muscle cells is pivotal in vascular aging. While the long non-coding RNA JPX has been shown to induce smooth muscle cell senescence, its role in EC senescence remains unknown. Senolytics (dasatinib + quercetin, D + Q) can eliminate senescent cells and attenuate the senescence-associated secretory phenotype (SASP), but their mechanisms in ECs are unclear. Here, we investigated the interplay between Senolytics and JPX in human umbilical vein endothelial cells (HUVECs). Using a lipopolysaccharide (LPS)-induced senescence model, we found that Senolytics alleviated endothelial senescence while suppressing the upregulation of JPX observed in senescent HUVECs. Functional assays showed that JPX knockdown inhibited, whereas JPX overexpression aggravated, EC senescence. Mechanistically, JPX interacted with bromodomain-containing protein 4 (BRD4) and transcription factor p65 to form a JPX-BRD4-p65 complex that promoted SASP expression. In vivo, Senolytics disrupted this complex and effectively mitigated endothelial senescence. Collectively, our study identifies JPX as a key regulator of vascular endothelial senescence and reveals that Senolytics exert anti-senescent effects by antagonizing the JPX-BRD4-p65 complex, providing novel mechanistic insights and potential therapeutic targets for vascular aging-related diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang 324000, China.
- Department of Pharmacy, Guangdong Women and Children Hospital, Guangzhou 511442, China.
- Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang 324000, China. Electronic address: qzrmyyzhl@wmu.edu.cn.
- Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang 324000, China. Electronic address: 276784489@wmu.edu.cn.
Förderung
- Wu Jieping Medical Foundation
- Guangdong Medical Research Foundation
Zitieren
APA
Mao, K., Zhu, W., Sun, H., Zheng, H., & Fu, Z. (2026). The anti-aging drug Senolytics alleviates vascular endothelial cell senescence by antagonizing the JPX-BRD4-p65 complex. Cellular Signalling, 139, 112342. https://doi.org/10.1016/j.cellsig.2025.112342
Vancouver
Mao K, Zhu W, Sun H, Zheng H, Fu Z. The anti-aging drug Senolytics alleviates vascular endothelial cell senescence by antagonizing the JPX-BRD4-p65 complex. Cellular Signalling. 2026;139:112342. doi:10.1016/j.cellsig.2025.112342
BibTeX
@article{Mao2026,
author = {Mao, Kaili and Zhu, Wensi and Sun, Huayu and Zheng, Hongliang and Fu, Zhenling},
title = {The anti-aging drug Senolytics alleviates vascular endothelial cell senescence by antagonizing the JPX-BRD4-p65 complex},
journal = {Cellular Signalling},
year = {2026},
volume = {139},
pages = {112342},
doi = {10.1016/j.cellsig.2025.112342}
}
EUVIMED